On June 12, 2026, the 2nd Global Cardiovascular Conference (Global Cardiovascular Conference, GCC 2026) was held at the Beijing Zhongguancun Exhibition Center Conference Hall.

As an important component of MedTech (Siyu MedTech)'s annual MedTech conference series, this year's conference attracted over 600 professional guests from hospitals, research institutes, innovative enterprises, investment institutions, and industrial service platforms. The conference focused on hot directions including structural heart disease, coronary intervention, heart failure treatment, intravascular imaging, cardiovascular artificial intelligence, and interventional robots, jointly exploring the development trends and clinical transformation pathways of cardiovascular innovative technologies.

On-site at the conference, the 2026 Global Cardiovascular Innovation Awards were officially unveiled. This year's awards included two categories: the Cardiovascular Innovative Device Award and the Cardiovascular Application Innovation Award. The Cardiovascular Innovative Device Award primarily focused on representative products and enterprises that had obtained innovative medical device approval from the National Medical Products Administration (NMPA), entered the innovative channel, or achieved key technological breakthroughs. The Cardiovascular Application Innovation Award focused on the application value and promotion practice of innovative technologies in real clinical scenarios.

Special Note: MedTech organizes awards twice annually. The judging panel can only select from registered applicants. Please follow the November announcement and actively apply to participate.

The award winners are listed below (in no particular order).

2026 Cardiovascular Innovative Device Award

4 Winners

Venus Medtech

Award Citation:

Hangzhou Venus Medtech Co., Ltd. has long focused on the structural heart disease interventional treatment field, and is one of the important representative enterprises in transcatheter valve therapy domestically.

In recent years, the company has continuously advanced the layout of multiple product pipelines including aortic valve, pulmonary valve, mitral valve, and tricuspid valve. Among them, the Cardiovalve transcatheter tricuspid valve replacement system has completed enrollment of all patients in the European confirmatory clinical study, and submitted the CE certification application to Europe in 2025; the next-generation dry-valve TAVR product Venus-PowerX focuses on innovative design around valve durability, paravalvular leak control, and a unique wire-control mechanism, and has currently entered the final stage of confirmatory clinical research.

Venus Medtech has built a relatively complete innovative product system around structural heart disease, continuously driving domestic valve interventional treatment technology toward broader indications and higher clinical value.

Shaoxing Meio Cardinav Medical Technology Co., Ltd.

Award Citation:

Shaoxing Meio Cardinav Medical Technology Co., Ltd. focuses on cardiac interventional navigation and electrophysiology surgical robot R&D, and is one of the earlier domestic innovative enterprises to lay out magnetic navigation cardiac interventional robots.

The company's developed TITIAN® Cardiac Electrophysiology Interventional Device Control System can assist physicians in completing precise catheter manipulation, reducing the risk of long-term operator exposure to X-ray environments; the RAPHAELLO® Flexible Magnetic Navigation Surgical Control System achieves precise catheter positioning and control through electromagnetic navigation technology, for use in complex arrhythmia mapping and ablation treatment.

Arrhythmia interventional treatment places extremely high demands on catheter stability, operational precision, and navigation capabilities. Meio Cardinav continues to carry out technological innovation around electrophysiology surgical robots, providing a new technical pathway for the development of domestic cardiac interventional robots.

Enlight Medical Technologies (Shanghai) Co., Ltd.

Award Citation:

Enlight Medical Technologies (Shanghai) Co., Ltd. has long focused on structural heart disease interventional treatment device R&D.

The company's independently developed transcatheter mitral valve clip system received NMPA approval in 2026, indicated for the treatment of high surgical risk degenerative mitral regurgitation patients. The product optimizes locking mechanism design, clamping control, and implantation system and other key links, which can improve leaflet capture efficiency and implantation stability.

Mitral regurgitation is one of the important treatment directions in the structural heart disease field. Through continuous advancement of domestic mitral valve interventional treatment technology innovation, Enlight Medical provides minimally invasive treatment options for more patients, and further enriches the domestic structural heart disease interventional product layout.

BrioHealth Technologies

Award Citation:

Suzhou BrioHealth Technologies Co., Ltd. has long focused on artificial heart R&D and industrialization, and is one of the important innovative enterprises in China's artificial heart field.

The company's first product, CH-VAD, received NMPA approval in 2021, becoming China's first fully magnetically levitated implantable artificial heart product; the upgraded product CH-VAD Plus received approval at the end of 2025. The new-generation product BrioVAD has obtained FDA clinical trial approval in the United States, and is simultaneously advancing European clinical research.

Around key technologies such as fully magnetic levitation technology, fluid dynamics optimization, and energy and information transmission, BrioHealth Technologies has established a complete technical system. Its continuously advancing global clinical layout also demonstrates the capability of domestic high-end life support equipment to participate in international competition.

2026 Cardiovascular Application Innovation Award

2 Winners

HORIMED

Award Citation:

Tianjin HORIMED Technology Co., Ltd. has long focused on intravascular ultrasound (IVUS), optical coherence tomography (OCT), and multimodal intravascular imaging technology R&D, and is one of the few domestic platform enterprises that simultaneously masters IVUS and OCT core technologies.

The company continues to carry out innovative layout around OCT, IVUS, OCT-IVUS fusion systems, and OCT-NIRS fusion technology. Among them, the OCT-NIRS system achieves synchronous completion of vascular structure imaging and lipid plaque identification through single-source dual-modality technology, providing new technical means for vulnerable plaque assessment.

In terms of clinical application, the company jointly initiated multicenter clinical research with Zhongshan Hospital, Fudan University, promoting new intravascular imaging technologies to form evidence-based medical evidence. HORIMED continues to advance the application of intravascular imaging technology in coronary intervention diagnosis and treatment, providing more imaging support tools for precision PCI.

Artery Planner

Award Citation:

Hangzhou Artery Planner Technology Co., Ltd. focuses on cardiovascular functional diagnostic product R&D based on computational fluid dynamics technology.

The company's core product, Artery Planner FFRCT, has received NMPA Class III medical device registration certificate and EU CE certification, and can complete non-invasive functional assessment through coronary CTA imaging. Its another product, FFR-Planner preoperative stent planning software, has also received a Class III medical device registration certificate, and can simulate the impact of different stent schemes on hemodynamic functional indicators before interventional treatment.

In recent years, coronary heart disease diagnosis and treatment is evolving from pure anatomical judgment toward functional assessment. Artery Planner combines high-performance computing with clinical decision-making, providing auxiliary decision-making tools for coronary intervention treatment, and also promoting the application and implementation of innovative technologies such as CT-FFR in real clinical scenarios.

Conclusion

From structural heart disease interventional treatment, artificial hearts, to intravascular imaging, functional assessment, and cardiac interventional robots, this year's award-winning enterprises cover important directions in cardiovascular device innovation.

Among them, the Cardiovascular Innovative Device Award showcases the new progress achieved by domestic innovative devices in fields such as valve intervention, artificial hearts, and structural heart disease treatment; the Cardiovascular Application Innovation Award reflects the application value of imaging technology, functional assessment, and clinical decision-making tools in real diagnosis and treatment scenarios.

Cardiovascular diseases remain one of the leading causes of death among Chinese residents. As innovative devices continue to receive approval, evidence-based evidence continues to accumulate, and clinical application gradually expands, China's cardiovascular medical device industry is moving from single-point breakthroughs toward systematic innovation. In the future, MedTech (Siyu MedTech) and CardioFuture will continue to focus on outstanding enterprises and teams with clinical value, innovation capabilities, and industrialization potential, jointly witnessing the development of China's cardiovascular innovation force.

June 12, 2026